Home » Investors » Press Releases » Invitation to the presentation of BICO’s Interim report Q1 2025

Single Press release

Invitation to the presentation of BICO’s Interim report Q1 2025

April 16, 2025 7:00 am

BICO’s Interim report Q1 2025 will be published on Tuesday April 29, 2025, at 07:00am CEST. Following the release of the report, a telephone conference with the opportunity to ask questions will be held in English at 10:00 am CEST on the same day, with President & CEO Maria Forss and CFO Jacob Thordenberg presenting the Interim report.

Information about the presentation and webcast
The presentation will be available on BICO’s website from 09:00am CEST.
https://bico.com/investors/

If you wish to participate via webcast, please use the link below. https://bico.events.inderes.com/q1-report-2025

If you wish to participate via teleconference, please register via the link below. After registration you will be provided with phone numbers and a conference ID to access the conference. You can ask questions verbally via teleconference. 
https://conference.inderes.com/teleconference/?id=5004715

For further information, please contact:
Jacob Thordenberg, CFO, BICO Group AB
Phone: +46 735 34 88 84
E-mail: jt@bico.com

The information was submitted for publication, through the agency of the contact person set out above, on April 16, 2025 at 7.00am CEST.

For inquires related to the presentation or teleconference or if you wish to send questions to the speakers, please contact BICO Investor Relations.
Phone: +46 735 46 57 77
E-mail: ir@bico.com

About BICO
BICO is a lab automation partner and provider of selected workflows to pharma and biotech. With 48,000+ instruments installed in over 65 countries, BICO products, software, and solutions are found in more than 3,500 laboratories, including the world’s top 20 pharmaceutical companies, and have been cited in over 11,900 publications. Operating through three business areas – Lab Automation, Life Science Solutions, and Bioprinting – BICO strives towards the vision to enable and automate the life science lab of the future. BICO is listed on Mid-Cap, Nasdaq Stockholm under BICO. www.bico.com

Attachments
Invitation to the presentation of BICO’s Interim report Q1 2025

Invitation to the presentation of BICO’s Interim report Q1 2025
Financials
Governance
The Share
News
Subscribe and stay updated with the latest news!
Subscribe
Copyright © 2025 BICO - The Bio Convergence Company - All rights reserved.

Contact us!

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.